Today's Top Gainer
Note:Top Gainer - Nifty 50 More
Diclofenac Potassium Softgel Capsules is part of Strides niche and small volume product portfolio with limited competition in the US market. According to IQVIA MAT data, the US market for Diclofenac Potassium Softgel Capsules, 25 mg is approximately US$ 30 million. Strides can launch the product earliest by September 2022 based on terms of settlement. On receiving full approval, the product will be manufactured at the companyfs Oral dosage facility at Bangalore and marketed by Strides Pharma Inc in the US Market.
Powered by Capital Market - Live News